Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.47 |
| ▸ | HRH2 | P25021 | 14/20 | 0.47 |
| ▸ | HRH1 | P35367 | 14/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094465 | 0.90 | HRH3 (0.56) | HRH3HRH2HRH1MEN1 | |
| SCHEMBL6989155 | 0.88 | HRH3 (0.48) | HRH3HRH2HRH1MEN1 | |
| SCHEMBL7166109 | 0.87 | HRH3 (0.44) | KCNH2HRH3HRH2HRH1MEN1 | |
| SCHEMBL2966798 | 0.86 | KCNH2 (0.53) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2970001 | 0.85 | KCNH2 (0.68) | KCNH2HRH3HRH2HRH1MEN1 | |
| SCHEMBL2963106 | 0.84 | KCNH2 (0.41) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2966190 | 0.84 | KCNH2 (0.49) | KCNH2HRH3HRH2HRH1MEN1 | |
| SCHEMBL5965551 | 0.83 | HRH3 (0.48) | HRH3HRH2HRH1MEN1 | |
| SCHEMBL3129013 | 0.82 | KCNH2 (0.55) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2960597 | 0.82 | MEN1 (0.56) | KCNH2HRH3HRH2HRH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | claimed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | claimed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | claimed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| US-7164017-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | ASTRAZENECA AB (SE) | 2006-04-06 | — | — | US | disclosed |
| EP-1503782-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| EP-1503783-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003092720-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003092721-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | KCNH2 9/4885HRH3 936/4885HRH2 680/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | KCNH2 11/4885HRH3 817/4885HRH2 1257/4885 |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HRH3 385/4885HRH2 505/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 12/4885HRH3 420/4885HRH2 556/4885 |
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | O60361, KCNH1, WNT3A | KCNH2 47/4885HRH3 1680/4885HRH2 833/4885 |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HRH3 385/4885HRH2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.